Author: Tim Stumm

Exicure, Inc. closes additional $11.2 million in private financing to advance its gene regulatory and immunotherapeutic programs

Financing Brings Total Raised to $31.5 Million in Last 45 Days SKOKIE, Ill.–(BUSINESS WIRE)–Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional Spherical Nucleic Acid (SNA™) constructs, today announced the closing of approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager Info Investments LTD, Knoll Capital […]

To access this content, you must purchase 1 Year Health News Illinois Subscription or 1 Year Group Subscription - Up to 5 Users, or log in if you are a member.

Read More

Advertise With Us